Possible utility of serum determinations of CA 125 and CA 27.29 in breast cancer management.
The utility of measurement of serum levels of the tumor associated antigens CA 125 and CA 27.29 in detecting the presence of disease and in monitoring changes in disease status was examined in 63 patients with breast cancer. In patients with clinically detectable disease the CA 125 level was elevated in 59%, the CA 27.29 level in 59.5% and one or both markers in 84.6%. Specificity for presence of disease was 83.6% for CA 125, 88% for CA 27.29, and 69.1% for the two markers combined. Changes in marker levels of more than 50% correlated with clinical changes in disease status in 58% of cases for either CA 125 or CA 27.29 alone. In 87.5% of cases with clinically progressive disease one or both marker levels increased by more than 50% from the previous levels. In no case with greater than 50% increase in a marker level was there regression of disease. Thus, the use of these markers in combination might have utility in cases where diagnosis of recurrent disease is difficult or where monitoring of response to treatment is hampered by lack of measurable disease.
Jensen
J L
JL
Department of Medicine, Cross Cancer Institute, Edmonton, Alberta-Canada.
Maclean
G D
GD
Suresh
M R
MR
Almeida
A
A
Jette
D
D
Lloyd
S
S
Bodnar
D
D
Krantz
M
M
Longenecker
B M
BM
D000230:Adenocarcinoma / Q000097:blood* / Q000175:diagnosis* / Q000556:secondary; D000951:Antigens, Neoplasm / Q000097:blood*; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood* / Q000175:diagnosis* / Q000556:secondary; D005260:Female; D006801:Humans; D008297:Male; D010865:Pilot Projects; D012680:Sensitivity and Specificity
D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor